Carmell Therapeutics Stock Market Value
| CTCX Stock | 0.25 0.01 4.17% |
| Symbol | Carmell |
Carmell Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carmell Therapeutics. If investors know Carmell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carmell Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.48 | Revenue Per Share 0.001 | Return On Assets (0.85) | Return On Equity (1.76) |
The market value of Carmell Therapeutics is measured differently than its book value, which is the value of Carmell that is recorded on the company's balance sheet. Investors also form their own opinion of Carmell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carmell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carmell Therapeutics' market value can be influenced by many factors that don't directly affect Carmell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carmell Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carmell Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carmell Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Carmell Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Carmell Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Carmell Therapeutics.
| 10/27/2024 |
| 11/26/2024 |
If you would invest 0.00 in Carmell Therapeutics on October 27, 2024 and sell it all today you would earn a total of 0.00 from holding Carmell Therapeutics or generate 0.0% return on investment in Carmell Therapeutics over 30 days. Carmell Therapeutics is related to or competes with SNDL, Keurig Dr, Apogee Enterprises, Westrock Coffee, Air Lease, Verra Mobility, and JD Sports. Carmell Therapeutics is entity of United States More
Carmell Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Carmell Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Carmell Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 103.81 | |||
| Value At Risk | (18.18) | |||
| Potential Upside | 18.52 |
Carmell Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Carmell Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Carmell Therapeutics' standard deviation. In reality, there are many statistical measures that can use Carmell Therapeutics historical prices to predict the future Carmell Therapeutics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (1.58) | |||
| Total Risk Alpha | (2.95) | |||
| Treynor Ratio | (0.11) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Carmell Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Carmell Therapeutics Backtested Returns
Carmell Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0276, which signifies that the company had a -0.0276% return per unit of risk over the last 3 months. Carmell Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Carmell Therapeutics' Standard Deviation of 14.01, risk adjusted performance of (0.03), and Mean Deviation of 8.36 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 6.91, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Carmell Therapeutics will likely underperform. At this point, Carmell Therapeutics has a negative expected return of -0.39%. Please make sure to confirm Carmell Therapeutics' jensen alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Carmell Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.51 |
Modest predictability
Carmell Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Carmell Therapeutics time series from 27th of October 2024 to 11th of November 2024 and 11th of November 2024 to 26th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Carmell Therapeutics price movement. The serial correlation of 0.51 indicates that about 51.0% of current Carmell Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.51 | |
| Spearman Rank Test | 0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Carmell Therapeutics lagged returns against current returns
Autocorrelation, which is Carmell Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Carmell Therapeutics' stock expected returns. We can calculate the autocorrelation of Carmell Therapeutics returns to help us make a trade decision. For example, suppose you find that Carmell Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Carmell Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Carmell Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Carmell Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Carmell Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Carmell Therapeutics Lagged Returns
When evaluating Carmell Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Carmell Therapeutics stock have on its future price. Carmell Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Carmell Therapeutics autocorrelation shows the relationship between Carmell Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Carmell Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.